Premium
Identification of G2/M targets for the MAP kinase pathway by functional proteomics
Author(s) -
Roberts Elisabeth C.,
Hammond Kasey,
Traish Abdulmaged M.,
Resing Katheryn A.,
Ahn Natalie G.
Publication year - 2006
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200600365
Subject(s) - phosphorylation , mapk/erk pathway , kinase , cyclin dependent kinase 1 , microbiology and biotechnology , dephosphorylation , mitosis , signal transduction , protein kinase a , biology , phosphoproteomics , blot , protein phosphorylation , chemistry , biochemistry , cell cycle , phosphatase , cell , gene
Although the importance of the extracellular signal‐regulated kinase (ERK) pathway in regulating the transition from G1 to S has been extensively studied, its role during the G2/M transition is less well understood. Previous reports have shown that inhibition of the ERK pathway in mammalian cells delays entry as well as progression through mitosis, suggesting the existence of molecular targets of this pathway in M phase. In this report we employed 2‐DE and MS to survey proteins and PTMs in the presence versus absence of MKK1/2 inhibitor. Targets of the ERK pathway in G2/M were identified as elongation factor 2 (EF2) and nuclear matrix protein, 55 kDa (Nmt55). Phosphorylation of each protein increased under conditions of ERK pathway inhibition, suggesting indirect control of these targets; regulation of EF2 was ascribed to phosphorylation and inactivation of upstream EF2 kinase, whereas regulation of Nmt55 was ascribed to a delay in normal mitotic phosphorylation and dephosphorylation. 2‐DE Western blots probed using anti‐phospho‐Thr‐Pro antibody demonstrated that the effect of ERK inhibition is not to delay the onset of phosphorylation controlled by cdc2 and other mitotic kinases, but rather to regulate a small subset of targets in M phase in a nonoverlapping manner with cdc2.